DACRIN research - underway

Open studies

Looking to participate in a DACRIN study? Below are links to eligibility information, participating organisations, and contact details for all currently open trials.

Please note: Not all DACRIN studies are open to public participation. Some trials may be limited to specific sites, populations, or referral pathways. If you're interested in getting involved, we encourage you to explore the listings below or contact us for more information.

Study title	Lead group	Further information
DACRIN 2025-2: Investigating New South Wales Opioid Treatment Program Clients’ perspectives regarding cannabis use in Opioid Treatment Programs: A Client Survey	DACRIN (SESLHD)	Contact us
DACRIN 2025-1: Clinical Review of Public Antenatal Medical Records	DACRIN (SESLHD/HNELHD)	Clinical Audit of Public Antenatal Medical Records
DACRIN 2024-2: Recollection of Event Memory following Drugs, Alcohol, and Stress in Adults Who Have Used Substances Previously (REMDAS)	DACRIN (NSLHD)	Participate in a study investigating amphetamine & alcohol use on memory and thinking
DACRIN 2024-1: The OLAM study. Randomised double blind placebo controlled trial of oral lisdexamfetamine for methamphetamine withdrawal	DACRIN (SVHN) &NCCRED	Lisdexamfetamine for methamphetamine withdrawal: clinical trial
DACRIN 2023-Survey: Discrete Choice Experiment for Increasing the Uptake of Routine Outcome Measures and Feedback	University of Queensland	Quality improvement
DACRIN 2021-4: The National Australian HCV Point-of-Care Testing Program (HCVPOCT).	The Kirby Institute	The National Australian HCV Point-of-Care Testing Program

Closed studies

These studies are no longer recruiting participants, but data collection is still ongoing. Final results are not yet available; however, some studies have interim findings already published—follow the links provided to learn more.
Stay tuned for updates as additional results are released.

Study title	Lead group	Further information
DACRIN 2022-1: A placebo-controlled randomised trial of cannabidiol (CBD) in the treatment of cannabis use disorder	DACRIN (SESLHD)	Bhardwaj et al. 2024
DACRIN 2021-3: Enhancing hepatitis C testing and treatment among people who inject drugs attending needle and syringe programs (TEMPO).	The Kirby Institute	The TEMPO Study
DACRIN 2019-3: Examining clinical outcomes and quality indicators for clients attending NSW public alcohol and other drug (AOD) treatment services (COQI Cohort Study)	DACRIN (SESLHD)	COQI Program
DACRIN 2017-5: ETHOS Engage: Enhancing treatment of Hepatitis C in Opioid Substitution Setting II (ETHOS II) partnership project to enhance hepatitis C care in drug and alcohol clinics.	The Kirby Institute	Conway, Valerio et al. 2021 Valerio, Alavi et al. 2021 Conway, Valerio et al. 2022 Valerio, Alavi et al. 2022

Analyses underway

The data collection phase for the DACRIN studies listed below has been successfully completed. Our researchers and partners are now analysing the data and preparing manuscripts focused on the primary outcomes for publication.

Some studies already have interim findings available—follow the links provided to explore these early insights. Final results will be shared as they become available.

Study title	Lead group	Outcomes
DACRIN 2023-5: The QuickStart Study: Evaluating same-visit rapid point-of-care hepatitis C testing and treatment in community clinics across Australia, to increase treatment uptake.	Burnett Institute	Not yet published
DACRIN 2023-2: Drug Intoxication Detection Film Study	DACRIN (NSLHD)	Not yet published
DACRIN 2023-1: The eCliPSE (Electronic Clinical Pathways to Service Excellence) project.	University of Newcastle	Not yet published
2023-Survey: New South Wales (NSW) Opioid Dependence Survey: Gaining knowledge on people with opioid dependence in NSW	UNSW NDARC	Not yet published
DACRIN 2021-1: Impact of long-acting depot buprenorphine on the high-risk post release period for people with opioid dependence (The Release Study)	DACRIN (HNELHD)	Not yet published
DACRIN 2019-6: Alcohol and Other Drugs (AOD) client concerns and wishes regarding cognitive impairment treatment (AOD Cog).	DACRIN (NSLHD)	Not yet published
DACRIN 2019-4: Driving perspectives, behaviours and concerns of consumers receiving opioid treatment	DACRIN (SLHD)	Not yet published
DACRIN 2019-2: Developing a clinical data laboratory for methamphetamine use in NSW: the MAData project.	DACRIN (SESLHD)	Intermin results: Black et al. 2022 Black et al. 2023
DACRIN 2016-5: Improving alcohol treatment outcomes: The impact of client, intervention and system variables on treatment outcomes (Alcohol Treatment Centre study)	University of Newcastle	Interim results: Hobden et al. 2023 Lawson et al. 2024